New cancer drug enters first human trials for advanced tumors
NCT ID NCT05306132
Summary
This is the first time a new cancer drug called ASKC202 is being tested in people. The study aims to find a safe dose and see how the body processes the drug, both alone and when combined with another drug called ASK120067. It will enroll about 150 adults with advanced solid tumors who have run out of standard treatment options, looking for early signs that the drugs might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital Affiliated to Tongji University
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
Contact
-
Xiangya Hospital Central South University
RECRUITINGChangsha, Hunan, China
Contact
Conditions
Explore the condition pages connected to this study.